Moreover, OIP5-AS1 directly targets miR-186-5p and subsequent clinical trials have confirmed that OIP5-AS1 was upregulated and miR-186-5p was downregulated in patients with pancreatic cancer. This evidence concerns the gene OIP5 and pancreatic neoplasm.